Home > Boards > US OTC > Medical - Drugs >

Vilacto Bio Inc (VIBI)

VIBI RSS Feed
Add VIBI Price Alert      Hide Sticky   Hide Intro
Moderator: stervc, declaes, UnderR8D, BLULLISH, TKane, Bud-Wiser
Search This Board: 
Last Post: 3/2/2021 1:58:34 AM - Followers: 307 - Board type: Free - Posts Today: 1

 
The Seagram Building
 
375 Park Avenue - Ste 2607

New York, NY 10152

https://vilactobio.com


https://vilactobio.com/ip-patent-rights/


PATENTS AND INTELLECTUAL PROPERTY RIGHTS

We protect our proprietary therapeutic products, assets and technologies by seeking and maintaining both domestic and international patent rights. These may cover products, compositions, methods of use, manufacturing processes, and other inventions that may be important to our business strategy. We also rely on trade secrets to protect aspects of our business.

Our competitive position depends on our ability to obtain patents on our technologies and our potential products, to defend our patents, to protect our trade secrets and to operate without infringing valid and enforceable patents or trade secrets of others. We seek licenses from others as appropriate to enhance or maintain our competitive position.

According to Patent No 8,637,075. a nanoparticle composition comprising colostrum Lactoactive® is formulated for treating diseases and/or conditions. Relieving the limited status due to the poor mechanical properties, rapid degradation, and in vivo clearance when bovine colostrum is used, our Lactoactive® is valuable to modify new bio/pharmaceutical industries.

In connection with our programs under Topical Drug, Systemic Drug & Supplement, and Cosmetics we hold a worldwide, perpetual, non-exclusive, license, with the right to sublicense, all the intellectual property related to the composition of matter of Topical Drug, Systemic Drug & Supplement and Cosmetics and plan to file U.S. and international patent applications.



https://microcapdaily.com/inside-scoop-on-vilacto-bio-inc-otcmkts-vibi/122822/
The Company recently announced it has revealed the initial five areas of development for its new LACTOACTIVE iTHER® compound. These include a bio-injection that could be useful in preventing metastasis of malignant tumor cells in cancer treatment due to the hydrocolloid potent (HA). An inhaler spray to prevent recurrent upper respiratory tract infections (based on a 2016 study. A vaccine injection for nanoparticle antibody source for a vaccine producer or a new variant of gelatin capsules for patients with arthritis and other joint inflammation with fewer side effects – especially hypertension if people with diabetes – than Glucosamine.

LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system. These development programs are part of Vilacto Bio’s LACTOACTIVE iTHER® plan to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.

https://microcapdaily.com/inside-scoop-on-vilacto-bio-inc-otcmkts-vibi/122822/
Inside Scoop on Vilacto Bio Inc (OTCMKTS: VIBI)
BY DANIEL MCCARTHY ON DECEMBER 27, 2018


Vilacto Bio Inc (OTCMKTS: VIBI) is an exciting stock that popped to $0.70 a share in October but has been dropping steadily since than recently hitting single digits.

Vilacto Bio Inc is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. The Company aims to further develop the Lactoactive® molecule for the purpose of increasing the quality of retail and medical skin cream products as well as licensing Lactoactive® molecule for the pharmaceutical industry.

The Company recently announced it has revealed the initial five areas of development for its new LACTOACTIVE iTHER® compound. These include a bio-injection that could be useful in preventing metastasis of malignant tumor cells in cancer treatment due to the hydrocolloid potent (HA). An inhaler spray to prevent recurrent upper respiratory tract infections (based on a 2016 study. A vaccine injection for nanoparticle antibody source for a vaccine producer or a new variant of gelatin capsules for patients with arthritis and other joint inflammation with fewer side effects – especially hypertension if people with diabetes – than Glucosamine.

LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system. These development programs are part of Vilacto Bio’s LACTOACTIVE iTHER® plan to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.

VIBI CEO Gert Anderson stated “Our own research suggests, and we firmly believe, that LACTOACTIVE iTHER® can contribute significantly to emerging therapies for treating a number of diseases, including cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and others.”

Earlier this year Vilacto Bio completed a two-month upgrade to the Denmark production facility, which is owned by Pharma GP, that produces its patented LACTOACTIVE nanoparticle compound. This upgrade will enable the company to manufacture even smaller LACTOACTIVE particles and enable Vilacto Bio to start production of its new LACTOACTIVE iTHER®.

In October VIBI announced it has launched its new skincare product, Carmen Electra by Vilact, based on the company’s LACTOACTIVE® compound. LACTOACTIVE® is the first variant of a patented particle the company has used to produce a range of popular skincare products. Customers have given Carmen Electra by Vilact rave reviews, and the new product won the “Buyers’ Choice” award at a ECRM event held in Las Vegas in June.

In addition to using the LACTOACTIVE® compound in its skin creams – now spun off as a separate business unit – Vilacto Bio is moving into biotech with its new LACTOACTIVE iTHER® compound. In the long run, Vilacto Bio expects LACTOACTIVE iTHER® to help develop further and even more powerful skincare solutions, along with therapeutic treatments for a range of medical conditions.

On November 30 VIBI announced it has secured the patent applications for LACTOACTIVE® covering rights in the US, Canada Europe and Hong Kong. The transaction was finalized this November. Ownership of the patent applications, which Vilacto Bio had been licensing the US rights from a Danish company, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound, and bolster its international IP ownership position.

The patent applications also cover the company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. LACTOACTIVE iTHER® is expected to generate new revenue streams in addition to the company’s LACTOACTIVE®-based therapeutic skincare range..”

The main active component of LACTOACTIVE® and LACTOACTIVE iTHER® is colostrum, a natural substance that Vilacto Bio has refined and processed into a potent nanoparticle concentrate. In NPDDS form, the compound can be applied in deeper layers of the skin and, when injected, can penetrate cell walls to act directly on cytoplasm. The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.



 

-------------------------------------------------------------------------------------Nothng to be put above this line-------------------------------------------------------------------------


 

THE FULL LINE OF VILACT® PRODUCTS

Vilact® products are the sole source of our breakthrough, patented SUPER-MOLECULE Lactoactive®, which regenerates skin at the cellular level, repairing and restoring aged and damaged skin.

Vilact® products penetrates skin deeper and more effectively than other premium skincare products, while being suitable for all skin types and offering restoration for sensitive skin caused by factors such as irritation, itchiness, eczema and atopic dermatitis.

Vilact | Skin Lotion with Almond Oil, Jojoba Oil, Shea butter, and Lactoactive® by Vilact® (4.2 FL.OZ / 125ml)
 
Vilact | Skin Cream for Sensitive Skin with Lactoactive® by Vilact® (4.2 FL.OZ / 125ml)
 
Vilact | Carmen Electra by Vilact® Skin Cream for Sensitive Skin with Lactoactive® (3.38 FL. OZ / 100ml)
 
 
Vilact | Skin Cream for Sensitive Skin Clinical Pump with Lactoactive® by Vilact® (16.9 FL.OZ / 500ml)
 
Vilacto | Lip Balm for Dry and Cracked Lips with Lactoactive® by Vilact® (.5 FL.OZ / 15ml)
 
 
Vilact | 24/7 Foot Cream with Lactoactive® by Vilact® (3.38 FL.OZ / 100ml)
 
 
 
 
 
 
NEWS & UPDATES

Sign up to get the latest on sales, new releases and more…

 

 
ABOUT VILACT®

Vilact® is produced by Vilacto Bio, an American company with roots in Scandinavia and that specializes in applying its patented Lactoactive® particle matrix within skincare and pharmaceutical applications.

 

Vilact® soothes and repairs skin like no other skincare product – even slowing the skin-aging process.

Our products can undo years of damage from environmental factors, restoring skin in virtually any condition a healthier, more youthful state

FOOTER MENU
Search
FAQ
Contact Us
Shipping Policy
Refund Policy
Privacy Policy
Vilact Beauty Blog
Affiliate Program
Skincare Guide
Terms & Conditions
Vilacto Bio, Inc.

 

 








Update: As of February 25, 2021


VIBI's OTCM-Status continues to be:


https://www.otcmarkets.com/stock/VIBI/overview



STOP SIGN 


Pink No Information















TERMINATION AND RELEASE AGREEMENT  





This Termination and Release Agreement (“Agreement”) is entered into as of this 8th day of November, 2018, by and among Vilacto Bio, Inc., a Nevada corporation (the “Vilacto”), Pharma GP APS, a Denmark corporation, and its sole shareholder, 9 Heroes APS, a Denmark corporation (together “Pharma GP”).  

WHEREAS, on or about April 19, 2017, we entered into a Stock Purchase Agreement (the “Purchase
Agreement”) with Pharma GP and its sole shareholder, 9 Heroes APS, a Denmark corporation, pursuant to which we agreed to purchase all of the outstanding shares of Pharma GP for the purchase price of
$6,000,000.00, payable as $3,000,000.00 in cash and the balance in shares of our common stock;  
WHEREAS, the closing of the Purchase Agreement was originally scheduled to occur on May 31, 2017; however, Vilacto has been unable to raise money needed to pay the purchase price under the Purchase Agreement;  

WHEREAS, the parties now desire to terminate and release each other and otherwise settle, compromise, dispose of, and release with finality, all claims, demands and causes of action, arising out of the Purchase Agreement dated April 19, 2017;  NOW, THEREFORE, in exchange for consideration, the adequacy of which is hereby acknowledged, the parties agree as follows:
 
Termination.
Subject to the terms and conditions of this Agreement, as of the date hereof, the Parties hereby terminate the Purchase Agreement and any and all rights, obligations or duties created thereunder.  

Coordination.
The parties agree to take whatever measures are necessary return to their respective positions as if the Purchase Agreement were never executed.  

Mutual Release.
Except for the obligations set forth in this Agreement, each party hereby releases, remises, acquits and forever discharges any other party to this Agreement and their related or controlled entities, and all of their directors, officers, members, managers, partners, employees, servants, attorneys, assigns, heirs, successors, agents and representatives, past and present, and the respective successors, executors, administrators and any legal and personal representatives of each of the foregoing, and each of them, from any and all claims, demands, actions, causes of action, debts, liabilities, rights, contracts, obligations, duties, damages, costs, expenses or losses, of every kind and nature whatsoever, and by whomever asserted, whether at this time known or suspected, or unknown or unsuspected, anticipated or unanticipated, direct or indirect, fixed or contingent, or which may presently exist or which may hereafter arise or become known, in law or in equity, in the nature of an administrative proceeding or otherwise, for or by reason of any event, transaction, matter or cause whatsoever, with respect to, in connection with or arising out of the Purchase Agreement or otherwise.   It is understood by the parties that the facts with respect to which the foregoing release is given may hereafter turn out to be other than or different from the facts now known to a party or the parties or believed by a party or the parties to be true, and each party therefore expressly assumes the risk of the facts turning out to be so different and agrees that the foregoing release shall be in all respects effective and not subject to termination or rescission by any such difference in facts.          

No Assignment.
The parties to this Agreement represent and warrant that neither they or their affiliated persons or entities have assigned or transferred any claim or interest herein or authorized any other person or entity to assert any claim or claims on its behalf with respect to the subject matter of this Agreement.  

Non-Disparagement.
The parties agree not to make any oral or written statements or otherwise take any action that is intended or may reasonably be expected to disparage the reputation, business, prospects or operations of any other party to this Agreement.  

Confidentiality.
The parties agree that they will keep confidential all information and trade secrets of one another or any of its subsidiaries or affiliates and will not disclose such information to any person without written prior approval or use such information for any purpose. It is understood that for purposes of this Agreement the term “confidential information” is to be construed broadly to include all material nonpublic or proprietary information. Vilacto shall promptly return any documents, records, data, books or materials of Pharma GP or its subsidiaries or affiliates in its possession or control and any of its work papers containing confidential information or trade secrets of Pharma GP or its subsidiaries or affiliates.  

Cooperation.
Each of the parties hereby agree to perform any and all acts and to execute and deliver any and all documents reasonably necessary or convenient to carry out the intent and the provisions of this Agreement.  

Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without reference to the principles of conflict of laws.  

Complete Agreement.
This Agreement represents the complete agreement among the parties concerning the subject matter in this Agreement and supersedes all prior agreements or understandings, written or oral, including the Agreement, the Security Agreements, the Advances, or otherwise. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives.  

Voluntary Agreement.
This Agreement has been entered into voluntarily and not as a result of coercion, duress, or undue influence. The parties acknowledge that they have read and fully understand the terms of this Agreement and have been advised to consult with an attorney before executing this Agreement.  

Successors and Assigns.
This Agreement shall be binding and inure to the benefit of the parties hereto, their predecessors, parents, subsidiaries and affiliated corporations, all officers, directors, shareholders, agents, employees, attorneys, assigns, successors, heirs, executors, administrators, and legal representatives of whatsoever kind or character in privity therewith.   

Counterparts.
This Agreement may be executed in counterparts, one or more of which may be facsimiles, but all of which shall constitute one and the same Agreement. Facsimile signatures of this Agreement shall be accepted by the parties to this Agreement as valid and binding in lieu of original signatures.  

Time for Performance.
The parties understand that time is of the essence with respect to each and every act required by this Agreement. Failure to perform any provision hereof in strict accordance with the Agreement shall be deemed a material breach of the Agreement.          
The parties to this Agreement have executed this Agreement as of the day and year first written above.  



VILACTO BIO INC. By /s/ Gert Andersen Printed Name: Gert Andersen Title: CEO  

PHARMA GP APS By /s/ Gert Andersen Printed Name: Gert Andersen Title: CEO  

9 HEROES APS By /s/ Gert Andersen Printed Name: Gert Andersen Title: CEO















OTC Markets Update on VIBI Status:
As of February 25, 2021,

VIBI's OTCM-Status continues to be:

https://www.otcmarkets.com/stock/VIBI/overview


STOP SIGN 

Pink No Information








 
 
Beware: All VIBI stock buyers, this company has a Red Stop Sign status, is deliquent with the SEC - not disclosing current finances
or current operating status to the SEC or to its own shareholders.

CAVEAT EMPTOR with VIBI - Buyers Beware!!! 


 
 



VIBI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#21223  Sticky Note BREAKDOWN COMING_"Vilacto has been unable to raise money TKane 02/22/21 12:00:42 PM
#21221  Sticky Note LOCKED OS 2.9 OS_LOCKED 1.5 BILLION FLOAT EST BLULLISH 02/22/21 11:32:31 AM
#16705  Sticky Note VIBI**Potential New Huge Revelation to Research... stervc 11/22/20 10:50:05 AM
#21445   It certainly has. What would someone new think Yooperman 03/02/21 01:58:34 AM
#21444   It's gotten silly on this board. doczaius 03/01/21 10:08:33 PM
#21443   $VIBI have very prominent people on board of ~MegaCash~ 03/01/21 03:06:26 PM
#21441   $VIBI is a great Pharma Company with awesome Products. ~MegaCash~ 03/01/21 03:04:12 PM
#21440   Carmen Electra by Vilact® https://www.youtube.com/watch?v=T4d-dfAElnI BLULLISH 03/01/21 03:04:02 PM
#21439   $VIBI news about Carmen Electra Vilact product! BLULLISH 03/01/21 03:02:54 PM
#21438   $VIBI~ Vilacto Bio, Inc. Contact Info ~MegaCash~ 03/01/21 03:02:06 PM
#21437   Carmen Electra with Bruce Wills BLULLISH 03/01/21 03:01:42 PM
#21436   $VIBI~ Vilacto Bio, Inc. Contact Info ~MegaCash~ 03/01/21 03:00:21 PM
#21435   $VIBI~ Vilacto Bio’s Vilact Skin Cream Wins Award BLULLISH 03/01/21 03:00:07 PM
#21434   $VIBI~ "Active" in Nevada SOS ~MegaCash~ 03/01/21 02:56:02 PM
#21433   $VIBI~ share structure. BLULLISH 03/01/21 02:55:34 PM
#21432   $VIBI CEO Gert Andersen holds 83.5 million common ~MegaCash~ 03/01/21 02:36:04 PM
#21431   $VIBI CEO Gert Andersen holds 83.5 million common shares BLULLISH 03/01/21 02:35:36 PM
#21430   $VIBI~ share structure ~MegaCash~ 03/01/21 02:34:29 PM
#21429   $VIBI patented products aired by KTLA5 BLULLISH 03/01/21 02:34:02 PM
#21428   $VIBI~ Vilacto Bio’s Vilact Skin Cream Wins Award ~MegaCash~ 03/01/21 02:19:22 PM
#21427   Great DD provided by stervc about VIBI connection BLULLISH 03/01/21 02:19:18 PM
#21426   $VIBI~ Actress and Model Carmen Electra Celebrity Endorsement ~MegaCash~ 03/01/21 02:11:26 PM
#21425   Also $VIBI and Cantabio IR Info the same!. BLULLISH 03/01/21 02:11:13 PM
#21424   $VIBI~Vilacto Bio offering natural alternatives to strong drugs ~MegaCash~ 03/01/21 02:10:16 PM
#21423   VIBI is a great Pharma Company with awesome BLULLISH 03/01/21 02:09:10 PM
#21422   $VIBI~ has so many products Products. ~MegaCash~ 03/01/21 02:08:25 PM
#21421   10 MILLION SHARES X.02=$200,000 BLULLISH 03/01/21 02:07:38 PM
#21420   $VIBI applications and intellectual property include the following: ~MegaCash~ 03/01/21 02:06:20 PM
#21419   LOADING OF $VIBI WITH AMAZING PRODUCTS BLULLISH 03/01/21 01:02:16 PM
#21418   We are ready !!! Tell them to hurry Bud-Wiser 03/01/21 12:48:52 PM
#21417   Agreed ...won’t be long now Bud-Wiser 03/01/21 12:39:16 PM
#21416   $VIBI~ Vilact® is produced by Vilacto Bio, an ~MegaCash~ 03/01/21 12:16:19 PM
#21415   $VIBI big things coming... _SuperPennies_ 03/01/21 12:10:40 PM
#21414   The CEO https://www.facebook.com/gert.andersen.351 The COO https://www.facebo TraderKen10 03/01/21 11:33:03 AM
#21413   Thank you TraderKen10 BDIY 03/01/21 10:37:32 AM
#21412   How will the requirements for companies currently quoted TraderKen10 03/01/21 10:24:23 AM
#21411   MORNING BLU RPh1 03/01/21 10:06:42 AM
#21410   HELLO AND GOOD MORNING $VIBI BLULLISH 03/01/21 10:02:18 AM
#21409   I've been here since 2018 and have not RPh1 03/01/21 06:52:57 AM
#21407   Please post link to CEO DIRTY RPh1 02/28/21 10:53:45 AM
#21403   No dodge. That DD provided several times before. TKane 02/27/21 12:56:19 PM
#21402   Nice Dodge on my question? beer$$money 02/27/21 11:55:58 AM
#21401   Part of DD provided to VIBI-newbies long ago. TKane 02/27/21 11:27:49 AM
#21399   How do you know this? Quote: "CEO DIRTY beer$$money 02/26/21 07:36:52 PM
#21398   Correct Of the 11 securities suspended this year beer$$money 02/26/21 07:07:05 PM
#21397   LOL YEAH LOOKING GOOD_https://investorshub.advfn.com/boards/read_msg.aspx BLULLISH 02/26/21 06:37:51 PM
#21396   Lots of misinformation. Carmen Electra never spokesperson for RPh1 02/26/21 06:25:51 PM
#21395   Oh my bad it was yesterday and that’s blazinw418 02/26/21 06:23:54 PM
#21394   Zero SEC suspensions today! Careful peeps of false information:( beer$$money 02/26/21 06:10:51 PM
#21393   MUST BE REFERRING TO SHORTING BLULLISH 02/26/21 06:10:42 PM
#21392   Plenty of companies out there with products. Most blazinw418 02/26/21 05:14:16 PM
#21391   FUNNY!! Except VIBIscam pennies will have Gert's mugshot! TKane 02/26/21 03:57:41 PM
#21390   $VIBI PENNIES COMING BLULLISH 02/26/21 03:51:10 PM
PostSubject
Consent Preferences